Spherix Incorporated (NasdaqCM: SPEX), a small biotech company that may be on the verge of a major drug in the diabetes fight. The key drug is Naturlose which is a naturally occuring sugar substitute. It is currently in phase III clinical trials and looks extremely promising.
The key to this drug is that it is natural. Not harmful to those that take it. It has shown to decrease weight, glucose spike blunting, treatment of type 2 diabetes, gut health and improved fetal survival and development. In addition, it tastes essentially the same as table sugar. It may eventually be a substitute in low calorie foods as well replacing the low or no calorie sweeteners currently on the market which have been tied to cancer.
SPEX is currently a micro cap biotech. This sector has been on fire lately and this stock looks to be on the verge of a major move. It is currently trading at $1.32 per share. Should this drug see positive phase III results and FDA approval, it could rocket to $5.00 in days.
Gareth Soloway
Chief Market Strategist
InTheMoneyStocks.com
